Phase 2
Completed N=26
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Source: ClinicalTrials.gov NCT02601469 ↗Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Number of Participants With HPA Axis Suppression — 3; 0; 21; 1 Participants
Summary
An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With HPA Axis Suppression |
3; 0; 21; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with a confirmed diagnosis of plaque psoriasis, patients 2-17 years of age with ≥ 10% BSA affected and patients age 18 years of age or older with ≥ 20% BSA affected
- Investigator Global Assessment (IGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity.
- Results from a cortisol response test that are considered normal and show no evidence of any abnormal HPA function or adrenal response
Exclusion Criteria
- Patients under 2 years of age.
- Investigator Global Assessment (IGA) of less than 3 (moderate) or greater than 4 (severe) at baseline.
- Current diagnosis of types of psoriasis other than stable plaque psoriasis (i.e., erythrodermic, exfoliative or pustular psoriasis).
- Results from a cortisol response test that show evidence of any abnormal HPA function or adrenal response
Data sourced from ClinicalTrials.gov (NCT02601469). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.